Daniel Reyner
Overview
Explore the profile of Daniel Reyner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
161
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dransfield M, Marchetti N, Kalhan R, Reyner D, Dixon A, Rheault T, et al.
Chron Respir Dis
. 2025 Jan;
22:14799731251314874.
PMID: 39854278
Background: The efficacy and safety of ensifentrine, a novel PDE3/PDE4 inhibitor, were previously evaluated in the ENHANCE-1 (NCT04535986) and ENHANCE-2 (NCT04542057) trials. Here, we present a pooled post-hoc subgroup analysis...
2.
Mahler D, Bhatt S, Rheault T, Reyner D, Bengtsson T, Dixon A, et al.
Expert Rev Respir Med
. 2024 Aug;
18(8):645-654.
PMID: 39106052
Background: Dyspnea is a critical component of chronic obstructive pulmonary disease (COPD). We report the effect of ensifentrine, a novel PDE3/PDE4 inhibitor, on dyspnea using pooled data from the Phase...
3.
van der Aart-van der Beek A, Cherney D, Laverman G, Stefansson B, van Raalte D, Hoogenberg K, et al.
Diabetes Obes Metab
. 2021 Apr;
23(8):1961-1967.
PMID: 33908683
High protein intake may increase intraglomerular pressure through dilation of the afferent arteriole. Sodium-glucose cotransporter-2 (SGLT2) inhibitors may reduce intraglomerular pressure through activation of tubuloglomerular feedback. Given these opposing effects,...
4.
Bailey C, Del Prato S, Wei C, Reyner D, Saraiva G
Diabetes Obes Metab
. 2019 Aug;
21(11):2564-2569.
PMID: 31364269
Dapagliflozin is associated with greater reductions in HbA1c and weight than saxagliptin in management of type 2 diabetes mellitus (T2DM). The present post hoc analyses compared the durability of these...
5.
Pollock C, Stefansson B, Reyner D, Rossing P, Sjostrom C, Wheeler D, et al.
Lancet Diabetes Endocrinol
. 2019 Apr;
7(6):429-441.
PMID: 30992195
Background: In patients with type 2 diabetes, intensive glucose control can be renoprotective and albuminuria-lowering treatments can slow the deterioration of kidney function. We assessed the albuminuria-lowering effect of the...
6.
Fioretto P, Del Prato S, Buse J, Goldenberg R, Giorgino F, Reyner D, et al.
Diabetes Obes Metab
. 2018 Jun;
20(11):2532-2540.
PMID: 29888547
Aims: Dapagliflozin is a selective inhibitor of sodium glucose co-transporter 2 (SGLT2). This study assessed the efficacy and safety of dapagliflozin 10 mg vs placebo in patients with type 2...